DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth Hormone

Withdrawn

Conditions: Pediatric Growth Hormone Deficiency

Interventions: Device: Sharps bin to collect used needles/injections

First Posted Date: 2023-11-02

Last Posted Date: 2024-02-09

Lead Sponsor: Pfizer

Registration Number: NCT06113952

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: PF-07976016
Drug: Placebo
Drug: Midazolam

First Posted Date: 2023-10-30

Last Posted Date: 2024-06-26

Lead Sponsor: Pfizer

Target Recruit Count: 110

Registration Number: NCT06106009

Locations: 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States

A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Sisunatovir suspension
Drug: Sisunatovir
Drug: Rabeprazole 40 mg
Drug: Rabeprazole 20 mg

First Posted Date: 2023-10-30

Last Posted Date: 2025-04-24

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT06105983

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2

Active, not recruiting

Conditions: Advanced or Metastatic Breast Cancer

Interventions: Drug: PF-07220060 CDK4 inhibitor
Drug: Fulvestrant
Drug: Everolimus
Drug: Exemestane

First Posted Date: 2023-10-27

Last Posted Date: 2025-03-18

Lead Sponsor: Pfizer

Target Recruit Count: 333

Registration Number: NCT06105632

Locations: 🇦🇷
Fundación CORI para la Investigación y Prevención del Cáncer, La Rioja, Argentina
🇦🇷
COE (Centro Oncológico de Excelencia), San Juan, Argentina
🇦🇷
Sanatorio Norte, Santiago del Estero, Argentina

and more 218 locations

A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants

Phase 3

Not yet recruiting

Conditions: Migraine

Interventions: Combination Product: Zavegepant 10 mg
Combination Product: Placebo - Control 1
Combination Product: Placebo - Control 2

First Posted Date: 2023-10-27

Last Posted Date: 2025-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 1280

Registration Number: NCT06103734

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

Phase 1

Terminated

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Placebo
Drug: Active

First Posted Date: 2023-10-26

Last Posted Date: 2025-04-23

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT06102174

Locations: 🇺🇸
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
Kaiser Permanente, Los Angeles, California, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India

Recruiting

Conditions: Transthyretin Amyloid Cardiomyopathy

Interventions: Drug: Tafamidis

First Posted Date: 2023-10-17

Last Posted Date: 2025-01-31

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT06086353

Locations: 🇮🇳
AIG Hospital, Hyderabad, India
🇮🇳
Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bangalore, Karnataka, India

A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.

Recruiting

Conditions: COVID-19

Interventions: Other: Disease description
Drug: SoC

First Posted Date: 2023-10-17

Last Posted Date: 2024-01-19

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT06085924

Locations: 🇨🇳
Pfizer Limited, Taipei, Taiwan

A Study to Learn About the Study Medicine - Precedex in Children From Japan.

Active, not recruiting

Conditions: Sedation

Interventions: Drug: Dexmedetomidine Hydrochloride

First Posted Date: 2023-10-17

Last Posted Date: 2025-02-14

Lead Sponsor: Pfizer

Target Recruit Count: 110

Registration Number: NCT06085573

Locations: 🇯🇵
Pfizer, Toykyo, Japan

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Completed

Conditions: Breast Cancer

Interventions: Drug: Palbociclib
Drug: Aromatase Inhibitor

First Posted Date: 2023-10-17

Last Posted Date: 2024-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 779

Registration Number: NCT06086340

Locations: 🇺🇸
Pfizer New York, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy